4
Changes in Ownership
Beam Therapeutics Inc. Filed Acc 0000899243-21-039697
CEO sold 47,700 shares at an average $83.80 ($3,997,268)
- CEO acquired 27,700 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Evans John M. CEO | 2021-10-06 | Option exercise | +27,700 | $1.03 | $28,531 | 1,061,225 | D |
| Evans John M. CEO | 2021-10-06 | Sale | −3,149 | $82.72 | $260,485 | 1,058,076 | D |
| Evans John M. CEO | 2021-10-06 | Sale | −13,406 | $83.47 | $1,118,999 | 1,044,670 | D |
| Evans John M. CEO | 2021-10-06 | Sale | −10,444 | $84.45 | $881,996 | 1,034,226 | D |
| Evans John M. CEO | 2021-10-06 | Sale | −701 | $85.19 | $59,718 | 1,033,525 | D |
| Evans John M. CEO | 2021-10-06 | Sale | −2,171 | $82.71 | $179,563 | 200,829 | I |
| Evans John M. CEO | 2021-10-06 | Sale | −9,863 | $83.49 | $823,462 | 190,966 | I |
| Evans John M. CEO | 2021-10-06 | Sale | −7,566 | $84.45 | $638,949 | 183,400 | I |
| Evans John M. CEO | 2021-10-06 | Sale | −400 | $85.24 | $34,096 | 183,000 | I |
| Derivatives | |||||||
| Evans John M. CEO | 2021-10-06 | Option exercise · Stock Option (Right to Buy) | −27,700 | 331,645 | D | ||
| Open-market sales · 47,700 sh · avg $83.80 · $3,997,268 | |||||||
Loading xslF345X03/doc4.xml…